Why Invest
A Compelling Opportunity
- First-in-class triple-action mechanism — no direct competitive overlap in pediatric CNS
- Validated DNX2401 backbone eliminates key de-risking uncertainty at IND stage
- Orphan Drug Designation eligibility: 10-year market exclusivity + priority review
- Rare disease market: premium pricing, lower trial size requirements, faster approval
- Strong academic and institutional partnerships across Spain, Europe, USA, and Australia
We are in active conversations with institutional investors, family offices, and strategic pharma partners. The round is open.